Oral Cancer Screening for Early Detection of Premalignant Disorders (PMOD)
PMOD
Screening for Oral Cancer for Early Detection of Premalignant Disorders
1 other identifier
interventional
200
1 country
1
Brief Summary
Cancer is a complex disease; its different causes and types have a strong impact on patient treatment and prognosis. To improve understanding of the disease, its causes and progression, the investigators will develop a simple, cost-effective system for continuous control of mucosal lesions with non-invasive brush biopsy that can be managed in primary dental care, as an alternative to tissue biopsy in order to reduce the number of oral cavity cancers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Aug 2023
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2022
CompletedFirst Posted
Study publicly available on registry
March 25, 2022
CompletedStudy Start
First participant enrolled
August 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2029
September 8, 2023
September 1, 2023
6.4 years
March 8, 2022
September 6, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Numbers of cancers diagnosed by brush sampling
5 years
Study Arms (2)
Brush biopsy
EXPERIMENTALBrusch biopsy at baseline and at 3 or 6 months
Care as usual
ACTIVE COMPARATORControl at 3 or 6 month, surgical biopsy when needed
Interventions
Brush sampling instead of surgical biopsy for control of reaccurance
Eligibility Criteria
You may qualify if:
- Persons 18 years of age or older who have the clinical diagnosis of leukoplakia, erythroplakia or proliferative verrukös leukoplakia
You may not qualify if:
- People who cannot read and understand information in Swedish.
- Ongoing chemotherapy and/or radiotherapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dalarna County Council, Swedenlead
- Uppsala Universitycollaborator
Study Sites (1)
Kristina Edman
Falun, Dalarna County, 79129, Sweden
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Public dental care
Uppsala University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD
Study Record Dates
First Submitted
March 8, 2022
First Posted
March 25, 2022
Study Start
August 1, 2023
Primary Completion (Estimated)
December 31, 2029
Study Completion (Estimated)
December 31, 2029
Last Updated
September 8, 2023
Record last verified: 2023-09